---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-148566"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2021-12-10T23:59:59+00:00"
generated_at: "2026-06-28T02:11:25.887512+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Journey Medical Q3 2021 net revenue $19.6M (+108% YoY); non-GAAP net income $3.5M

## Summary
- Net revenue $19.6M vs $9.4M in Q3 2020, up 108%.
- Non-GAAP net income $3.5M ($0.38 basic EPS) vs $0.6M in Q3 2020.
- Completed November IPO: 3.52M shares at $10, net proceeds $31.2M.
- New CFO appointed; DFD-29 Phase 3 first dosing expected Q1 2022.
- Cash and equivalents $21.7M as of Sep 30, 2021, up from $8.2M at Dec 31, 2020.

## SEC filing metadata
- accession: 0001104659-21-148566
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2021-12-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465921148566/0001104659-21-148566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465921148566/tm2135030d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-148566
- JSON: https://secwatch.observer/filing/0001104659-21-148566.json
- Plain text: https://secwatch.observer/filing/0001104659-21-148566.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.